Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANI PHARMACEUTICALS, INC.

(ANIP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ANI Pharmaceuticals : Launches Generic Hypertension Drug

09/17/2021 | 07:57am EDT


ę MT Newswires 2021
All news about ANI PHARMACEUTICALS, INC.
09/20ANI PHARMACEUTICALS : to Present at Cantor Virtual Global Healthcare Conference 2021
BU
09/17ANI PHARMACEUTICALS : Launches Generic Hypertension Drug
MT
09/17ANI PHARMACEUTICALS : Announces Launch of Nebivolol Tablets
BU
09/17ANI Pharmaceuticals, Inc. Announces Launch of Nebivolol Tablets
CI
08/31ANI PHARMACEUTICALS : Says FDA Accepts for Review Its Supplemental New Drug Application fo..
MT
08/31ANI PHARMACEUTICALS : FDA Accepts Application for Cortrophin Gel Revival
DJ
08/31ANI PHARMACEUTICALS : Announces FDA Acceptance of Purified Cortrophin« Gel Supplemental Ne..
BU
08/31Ani Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin« Gel Supplemental N..
CI
08/06ANI PHARMACEUTICALS : Posts Lower Q2 Earnings, Revenue Increases
MT
08/06ANI PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
More news
Analyst Recommendations on ANI PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 210 M - -
Net income 2021 -15,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -30,3x
Yield 2021 -
Capitalization 467 M 467 M -
Capi. / Sales 2021 2,23x
Capi. / Sales 2022 1,91x
Nbr of Employees 369
Free-Float 77,0%
Chart ANI PHARMACEUTICALS, INC.
Duration : Period :
ANI Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANI PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 38,54 $
Average target price 45,00 $
Spread / Average Target 16,8%
EPS Revisions
Managers and Directors
Nikhil Lalwani President, Chief Executive Officer & Director
Stephen P. Carey Chief Financial Officer, Secretary & VP
Patrick D. Walsh Chairman
James G. Marken Senior VP-Operations & Product Development
Robert E. Brown Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ANI PHARMACEUTICALS, INC.32.71%467
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657